ExoFlo™ Infusion for Post-Acute COVID-19 and Chronic Post-COVID-19 Syndrome

Summary

This is a Phase I/II trial to evaluate the safety and efficacy of intravenous (IV) administration of bone marrow mesenchymal stem cell derived extracellular vesicles (EV), ExoFlo, as treatment for Post-Acute COVID-19 and Chronic Post-COVID-19 syndrome.

Timeline

Start

2024-11

Primary completion

2024-11

Completion

2024-12

Outcome

Outcome not reported

Stopped: “Study no longer part of development plan.”

Drugs

Indications